Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Need for further surgery particularly high in younger men and serious complications surprisingly common in older people, say researchers.

The risks associated with shoulder replacement surgery for arthritic conditions are higher than previously estimated, particularly for people under 60 and over 85 years old, finds a study published by The BMJ today.

“The decision to undergo a shoulder replacement is a balance between the potential benefits and possible risks of surgery. 
- Richard Craig, lead author 

The findings show that one in four men aged 55-59 years is at risk of needing further revision surgery, especially during the first five years after surgery. What’s more, the risks of serious adverse events (such as heart attacks, major blood clots and chest infections) within 90 days of surgery are much higher than previously estimated, particularly in those over 85 years. 

The researchers say these risks should be made clearer to patients before they opt for surgery, and they caution against “unchecked expansion” of shoulder replacement surgery in both younger and older patients.

“The decision to undergo a shoulder replacement is a balance between the potential benefits and possible risks of surgery. We hope that patients and surgeons will use the information from our study to help them decide whether to go ahead with a shoulder replacement for arthritis.”, says lead author Richard Craig.

The number of shoulder replacements performed is expanding rapidly. In adults aged over 50, surgery increased more than 5.6-fold, from 1,018 cases in 1998 to 5,691 in 2016.

Despite this growth, no study has reported on the lifetime risk of further surgery, and serious events are considered rare.

So our researchers used hospital and mortality records to calculate precise risk estimates of serious adverse events and lifetime risk of revision surgery, after non-emergency (elective) shoulder replacement surgery for arthritis.

The study included just over 58,000 procedures carried out in nearly 52,000 adults (aged 50 or over) across England between April 1998 and April 2017. Average age at surgery was 72 years and average follow-up was 5.6 years.

Rates of serious adverse events were calculated at 30 and 90 days after surgery and included major blood clots, heart attack, infections, stroke and death. Revision risk according to age and sex was estimated at 3, 5, 10, and 15 years after surgery and over a patient’s lifetime.

The lifetime risk of revision surgery ranged from 1 in 37 in women aged 85 years and older to 1 in 4 in men aged 55-59 years. The risks of revision were highest during the first five years after surgery. 

The risk of any serious adverse event at 30 days post-surgery was 1 in 28, and at 90 days post-surgery was 1 in 22. 

Serious adverse events were associated with increasing age, existing illness (comorbidity), and male sex - 1 in 9 women and 1 in 5 men aged 85 years and older experienced at least one serious adverse event within 90 days.

This is an observational study, and as such, can’t establish cause, and the researchers cannot rule out the possibility that some unmeasured factors may have influenced the results. 

Nevertheless, they say these risks are higher than previously considered, and for some could outweigh any potential benefits.

They say younger patients, particularly men, need to be aware of a higher likelihood of early failure of shoulder replacement and the need for further and more complex revision replacement surgery. And they suggest that all patients should be counselled about the risks of serious adverse events. 

As the population ages, it is likely that demand for shoulder replacement in older people will continue to increase, and the higher risk of adverse events described here should form part of shared decision making with patients, they conclude. 

 

Supported by

Royal College of Surgeons logo

Versus Arthritis logo

   NIHR logo

National Joint Registry logo

Similar stories

Professor Dani Prieto-Alhambra elected to ISPE Board of Directors

Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, has been elected as the Academic representative for Europe and Africa on the International Society of Pharmaco-Epidemiology Board of Directors.

New research from the Kennedy Institute of Rheumatology identifies a role for CD200 in limiting atherosclerosis

A new study published in Circulation Research shows that CD200, an inhibitory immune checkpoint, reduces the development of atherosclerosis.

EPSRC funds research to avert an antibiotics apocalypse

Researchers at the Kennedy Institute join a collaboration to find new ‘drug-free’ ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.

Research finds that surgery for Dupuytren’s disease is effective, but repeat operations come with higher risks

Research by NDORMS Dominic Furniss, Professor of Plastic and Reconstructive Surgery, finds that surgery for the common hand disorder Dupuytren’s disease is safe and effective. However, repeat surgery could carry higher risks of complications such as finger amputation.

Celebrating World Clubfoot Day

More than 30,000 children in Africa are born with clubfoot each year. With treatment simply not available where they live, many thousands of these children get no treatment and end up with severe deformities that make it hard and very painful to walk.

Repurposed drug can induce remission of inflammatory arthritis

Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.